A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs PF 5221304 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Jan 2019 Planned End Date changed from 1 Apr 2019 to 8 Apr 2019.
- 02 Jan 2019 Planned primary completion date changed from 1 Mar 2019 to 11 Mar 2019.
- 19 Dec 2018 Planned End Date changed from 8 Mar 2019 to 1 Apr 2019.